SynthesisPituitary2026
Pituitary stalk biopsy - A systematic review of the safety and efficacy of stalk lesion biopsy.
Synthesis in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA myriad of pathological process may involve the pituitary stalk (infundibulum), and despite extensive investigations, biopsy is often required. Due to the rarity of the procedure, the risks and yield of stalk biopsy are not well known, with important implications for clinical decision making.
methodsA systematic review was performed in accordance with the PRISMA statement. Studies that reported diagnostic yield and complication rates after stalk biopsy were included. Bias was assessed using ROBINS-V2.
resultsA total of 13 studies, including 832 patients and 406 biopsies were included. Mean time from diagnosis to biopsy was 11 months. Preoperative visual symptoms were seen in 29.1%, AVP-deficiency (diabetes insipidus) in 71.0%, and hypopituitarism in 66.3%. Biopsy was predominately performed through the endoscopic transsphenoidal approach (70.9%). Diagnostic yield was 95.8%, and complications included postoperative CSF leak (1.6%), visual worsening (1.6%), new cranial nerve palsy (1.2%), new permanent AVP-deficiency (9.0%), new hypopituitarism (15.7%), and meningitis (2.7%).
conclusionPituitary stalk biopsy is a high yield and safe diagnostic test, with low periprocedural morbidity. The rate of new endocrinopathy compares favourably to the natural history of progressive stalk disease. Stalk biopsy could be considered earlier in the workup of undifferentiated progressive or symptomatic stalk lesions to avoid unnecessary delays in diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.